- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00155974
Rapid Vaccination of Hard-To-Reach Populations
Rapid Vaccination of Hard-to-Reach Populations
The purpose of this study is to develop and determine the effectiveness of a multi-level community participatory intervention designed to rapidly immunize hard-to-reach populations, including substance users, within disadvantaged minority communities.
Specific Aims of the project are as follows:
- To identify the relative contributions of personal factors and structural barriers to immunization status in hard-to-reach populations.
- To estimate the size of the hard-to-reach population in specified disadvantaged urban communities using venue-based sampling, probability-based sampling, capture-recapture methods and modified Delphi techniques.
- To compare vaccination rates in hard-to-reach populations between neighborhoods that receive a community-based vaccine outreach intervention versus neighborhoods where vaccines are offered through standard public health programs, using an incremental crossover multilevel community intervention design.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10029
- Recruiting
- Center for Urban Epidemiologic Studies, The New York Academy of Medicine
-
Contact:
- Micaela H Coady, MS
- Phone Number: 212-822-7277
- Email: mcoady@nyam.org
-
Contact:
- Danielle Ompad, PhD
- Phone Number: 212-419-3589
- Email: dompad@nyam.org
-
Principal Investigator:
- David Vlahov, PhD
-
Principal Investigator:
- Sandro Galea, MD, DrPH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
The possible participant pool for this project is the adult population (over the age of 18) of 8 circumscribed neighborhoods in East Harlem and South Bronx in NYC. These neighborhoods have a total population of approximately 24,000 people (based on the 2000 US Census) and we anticipate that up to 4,000 may be among the eligible hard-to-reach populations that are the target of this proposal. We will identify eligible populations through a brief survey instrument. During the intervention phase of this study, persons who are eligible to receive influenza vaccination will be offered influenza vaccination. Eligibility criteria for influenza vaccination are the eligibility criteria established by the Advisory Committee on Immunization Practices guidelines. These will be determined as part of the standard data collection instrument. Eligible persons include persons over the age of 65 and persons concurrent comorbidity including immunosuppression (HIV or active injection drug use), chronic pulmonary or cardiovascular disorder (including asthma), or chronic metabolic diseases (including diabetes mellitus, renal or hepatic dysfunction).
Exclusion Criteria:
Exclusion criteria include an allergy to vaccines, an allergy to eggs, inability to provide consent, currently under care of a physician and a plan to receive influenza vaccine in the near-future, or having already received the influenza vaccine during this year (CDC 1999).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
|---|
|
Compare vaccination rates in selected neighborhoods before and after a multilevel community-based participatory intervention trial.
|
Secondary Outcome Measures
Outcome Measure |
|---|
|
Determine and identify the relative contributions of personal factors and structural barriers to immunization status in hard-to-reach populations.
|
|
Estimate the size of the hard-to-reach populations.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: David Vlahov, PhD, Center for Urban Epidemiologic Studies, The New York Academy of Medicine
- Principal Investigator: Sandro Galea, MD, DrPH, Center for Urban Epidemiologic Studies, The New York Academy of Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 091603
- DA017004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.